Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin

Wenderoth, U.K.; Jacobi, G.H.

Annales d'Urologie 20(2): 95-97

1986


ISSN/ISBN: 0003-4401
PMID: 3087269
Document Number: 274990
Patients with metastatic prostatic cancer were treated by means of an LHRH agonist, Buserelin, by nasal administration. The serum testosterone levels were permanently decreased to castration levels in all patients. The objective response rate (CR + PR) was 50%.

Document emailed within 1 workday
Secure & encrypted payments